Bruce Buckingham

Bruce Buckingham, MD, Professor, Department of Pediatrics, Division of Endocrinology and Diabetes, Stanford University School of Medicine, Emeritus - Active

Research Description: Dr. Buckingham's research focuses on automated insulin delivery, insulin infusion sets, continuous glucose monitoring, rapid acting insulins, and complications of diabetes, such as neurocognitive changes. He was the PI at Stanford for the NIH sponsored DirecNet study group and the JDRF multicenter continuous glucose monitoring (CGM) study. He was PI on the first studies testing the Medtronic 670G hybrid closed-loop system and is now testing the 780G system. He has conducted studies with Ed Damiano and the Bionic Pancreas, and Dr. Buckingham was the PI testing an insulin-only version of the Bionic Pancrea which is now part of an NIH trial being conducted at Stanford. He has conducted several NIH multicenter collaborative studies testing in home closed-loop control with Roman Hovorka at Cambridge, the University of Virginia and TypeZero. He is also conducting studies with Insulet on their automated insulin delivery system. His team is also developing long term insulin infusion sets (IDE G150256). As part of the DirecNet study group he completed longitudinal studies of MRI and neurocognitive changes in children with diabetes, relating changes to their glycemic control measured by A1c and CGM, in collaboration with SDRC members, Drs. Reiss, Hood, Wilson, Maahs and Aye. He has evaluated newer insulins such as FIASP in closed-loop systems, and been involved in studies of novel insulins and co-formulations with Eric Appel as part of the SDRC. He has also conducted studies using an Apple watch to recognize the onset of eating tp trigger insulin delivery in a fully closed loop system.

Selected relevant publications (Stanford DRC Members in BOLD):

  1. Lal RA, Hsu L, Zhang J, Schøndorff PK, Heschel M, Buckingham B. Longevity of the novel ConvaTec infusion set with Lantern technology. Diabetes Obes Metab. 2021 Apr 6. doi: 10.1111/dom.14395. PMID: 33822472. 

  2. Maikawa CL, d'Aquino AI, Lal RA, Buckingham BA, Appel EA. Engineering biopharmaceutical formulations to improve diabetes management. Sci Transl Med. 2021 Jan 27;13(578). doi: 10.1126/scitranslmed.abd6726. Review. PubMed PMID: 33504649..2337/dc20-2125.  PubMed PMID: 33568403. 

  3. Tanenbaum ML, Iturralde E, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users. J Health Psychol. 2020 Mar;25(4):429-438. doi: 10.1177/1359105317718615. PMID: 28810490; PMCID: PMC7162558. 

  4. Lal RA, Ekhlaspour L, Hood K, Buckingham B. Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes. Endocr Rev. 2019 Dec 1;40(6):1521-1546. doi: 10.1210/er.2018-00174. PMID: 31276160; PMCID: PMC6821212.